Background: This study was conducted to measure the concentration of branched
| INTRODUCTION
Type 2 diabetes (T2D), the most prevalent form of diabetes, has affected more than 425 million people in the world. 1 Increased concentrations of branched-chain amino acid (BCAA), including leucine (Leu), isoleucine (Ile) and valine (Val) have been detected in obese and T2D
rodent models, such as Zucker diabetic fatty rat ob/ob mice and high-fat diet-induced diabetic mice. [2] [3] [4] [5] [6] Furthermore, metabolomics demonstrate that elevated BCAA concentrations are highly associated with the development of insulin resistance. [7] [8] [9] It has been reported that BCAA could stimulate the mammalian target of rapamycin and S6 kinase and phosphorylate insulin receptor substrate 1 on serine residues, impairing the insulin signaling pathway. [10] [11] [12] Decreased BCAA catabolism could contribute to insulin resistance and glucose intolerance, ultimately leading to T2D. 7 Increasing evidence has indicated that elevated BCAA concentrations could serve as useful markers for T2D. [13] [14] [15] [16] [17] The first step of BCAA catabolism is transamination catalyzed by branched-chain aminotransferase, which is expressed mainly in muscle, kidney, and heart, yielding corresponding branched-chain α-ketoacids (BCKAs). 18 BCKAs are then catalyzed by the branched-chain a-ketoacid dehydrogenase complex (BCKDC), which is the rate-limiting enzyme of BCAA catabolism. [19] [20] [21] Agus and colleagues report that the activity of Bckdc in liver comprises up to 60%-83% of the whole body Bckdc activity in rats. 22 The BCKDC is a multienzyme complex, consisting of E1 (with α and β components), E2, and E3, 23 and its activity is regulated by phosphorylation (inactivation) and dephosphorylation (activation) of the E1α component by BCKDC kinase (BCKDK) and BCKDC phosphatase, respectively. 24 Moreover, the gene BCKDHA encoding the BCKDC E1α component has been identified as a candidate gene associated with obesity and T2D. 25 It has been reported that knock out of Bckdk led to a significantly reduced blood BCAA concentration. 20 Increased BCAA concentrations have been observed in obesity and T2D rodent models, such as Zucker diabetic fatty rat, 3, 4, 6, 26 ob/ob mice 4 and high-fat diet (HFD)-induced mice 2 and T2D human. 13 In contrast, the BCAA concentrations in spontaneous T2D Otsuka Long-Evans Tokushima Fatty (OLETF) rats are lower than in controls, although the difference was not significant, 26 and BCAA concentrations in T2D young humans are significantly lower than in controls. 27 Together, these findings suggest that differences in BCAA concentrations occur between species and at different stages of life. However, BCAA concentrations in non-obese T2D GK rats have not been reported. Thus, we measured BCAA concentrations in three species-spontaneous T2D Goto-Kakizaki (GK) rats, induced T2D cynomolgus monkeys and T2D humansusing liquid chromatography tandem mass spectrometry (LC/MS).
Furthermore, it has been reported that Bckdha protein expression is decreased in the liver of obese T2D Zucker rats, 4 and liver BCKDC activity is significantly decreased in T2D rats. 26 It has also been reported that the enzymes in BCAA catabolism are decreased in adipose tissue and liver in ob/ob mice and fa/fa rats. 4 As the pattern of change in plasma BCAA concentrations and liver Bckdha and Bckdk expression in non-obese T2D GK rats has not yet been reported, we measured plasma BCAA concentrations and liver Bckdha and Bckdk gene expression in these rats.
| METHODS

| Experimental animals and blood collection
This study involved 50 T2D GK male rats and 50 control Wistar male rats obtained from SLAC Laboratory Animal Co., Ltd (Shanghai, China). The feeding regime was as previously described. 28 Rats were anesthetized using pentobarbital sodium (3%, 0.2 ml/100 g) and sacrificed by abdominal aortic exsanguination. Five control cynomolgus monkeys, five STZ-induced T2D cynomolgus monkeys and three diet-induced T2D cynomolgus monkeys were involved in this study. Diet-induced T2D was achieved as previously described in the diet-induced group. 
| Plasma glucose concentration measurements
A GLU Assay Kit (KOFA, China) and an automatic biochemistry analyzer (Hitachi 7020, Tokyo, Japan) were used to measure glucose concentration. Assays were carried out according to manufacturer's directions, with standards run in duplicate and experimental samples run in triplicate.
| Plasma insulin concentration measurements
Plasma insulin was measured with a Luminex MAGPIX using a Milli-
Milliplex, Germany). Assays were carried out according to manufacturer's directions, with standards run in duplicate and experimental samples run in triplicate.
| BCAA concentration measurements
The BCAA concentration of each plasma and serum sample was mea- 
| Statistical analysis
All data were expressed as means ± SD. Significant differences were assessed using a two-tailed Student's t test. P < 0.05 was considered statistically significant.
| RESULTS
| Cynomolgus monkey plasma glucose and
BCAA concentrations
The plasma glucose concentrations in STZ-induced and dietinduced T2D cynomolgus monkeys were both significantly increased compared with those in healthy cynomolgus monkeys (P < 0.001 and P < 0.01, respectively) ( Figure 1A) . The plasma BCAA concentrations in STZ-induced T2D cynomolgus monkeys were lower than those in controls, though the differences were not significant ( Figure 1B) . However, the plasma BCAA concentrations in diet-induced T2D cynomolgus monkeys were significantly lower than in controls (P < 0.01) ( Figure 1B) , in contrast to previous reports of significant increases in BCCA concentrations in this T2D model. 3, 5, 6 This difference might be due to differences in experimental species.
| Human serum glucose and BCAA concentrations
The serum glucose concentrations in prediabetic humans and T2D
humans were both significantly elevated compared to those in healthy humans (P < 0.001); the serum glucose concentrations in T2D humans were significantly higher than those in prediabetic humans (P < 0.01) (Figure 2A ). The BCAA concentrations in prediabetic humans were higher than in healthy humans, but not significantly ( Figure 2B ). T2D human BCAA concentrations were significantly increased in comparison with healthy humans (P < 0.001) ( Figure 2B ). These results in prediabetic humans and T2D humans indicate that differences in the trends and levels of BCAA exist at different periods during the progress of T2D. The rise in BCAA concentrations in T2D humans was in accordance with previous reports of significant increases in BCAA concentration.
32,33
| GK rat plasma glucose and insulin concentrations
The plasma glucose concentration in GK rats increased between 4 and 12 weeks, and then it began to decrease. In Wistar rats, the plasma glucose concentration also increased between 4 and 12 weeks ( Figure 3A) . The plasma glucose concentrations in GK rats were significantly increased compared to Wistar rats between 4 and 20 weeks (P < 0.001) ( Figure 3A) . The plasma insulin concentration in GK rats increased at 4 weeks and reached a maximum at 8 weeks, and then began to decline ( Figure 3B ). In contrast, the plasma insulin concentration in Wistar rats also rose from 4 weeks and reached a maximum at 8 weeks, but then the concentration remained steady until 16 weeks. The insulin concentration in GK rats was higher than in Wistar rats, although not significantly, at 8 weeks, but significantly lower than in Wistar rats at 4 (P < 0.01), 12 (P < 0.01), 16
(P < 0.001), and 20 weeks (P < 0.001).
| BCAA concentrations in GK and Wistar rats
GK rat BCAA concentrations were significantly lower than in Wistar rats at 4 and 8 weeks (P < 0.05 and P < 0.01, respectively), and remained lower at 12 and 16 weeks, though not significantly (Figure 4A) . The concentrations were above control levels, but not ZHANG ET AL.
| 307 significantly, at 20 weeks ( Figure 4A ). The plasma Leu concentrations in the GK rats were significantly reduced compared to controls between 4 and 12 weeks (P < 0.001), remained lower than in controls, but not significantly, at 16 weeks, and were higher than controls, though not significantly, at 20 weeks ( Figure 4B ). The plasma Ile concentrations in the GK rats were significantly lower than in control between 4 and 12 weeks (P < 0.01, P < 0.001, P < 0.01, at 4, 8, and 12 weeks, respectively) and lower than controls, though not significantly, at 16 weeks and 20 weeks (Figure 4C) . GK rat plasma Val concentrations were lower than controls, but not significantly, at 4 and 8 weeks, and higher than controls, but not significantly, from 12 weeks to 20 weeks ( Figure 4D ). The results indicated that GK rat BCAA concentrations were different at different stages of life. These GK rat concentrations are not in accordance with previous reports of significantly increased BCAA concentrations in rat models.
3,5,6
| Expression of Bckdha and Bckdk genes
Previous reports indicated that BCAA concentrations significantly increase and the expression of Bckdha encoding the rate-limiting enzyme BCKDHA is significantly reduced in T2D animal models. 
| DISCUSSION
In this study, BCAA concentrations were significantly reduced in diet-induced T2D cynomolgus monkeys (P < 0.01) and in GK rats at It has been reported that BCAA can increase glucose uptake and act as insulin secretagogues. 36, 37 Leu could stimulate glucose transport in skeletal muscle via phosphatidylinositol 3-kinase and the protein kinase C pathway. 38 Leu has been identified as an insulin secretagogue, as it can induce and enhance pancreatic β-cell insulin secretion through its oxidative decarboxylation, as well as allosterically activate glutamate dehydrogenase. 37, 39, 40 In addition, Leu supplementation can improve glucose metabolism, and reduce dietinduced insulin resistance in mice. 41 Moreover, it has been reported that BCAA reduce oxidative stress in pancreatic islets and ameliorate β-cell dysfunction, involving c-Jun N-terminal kinase, protein kinase D1 and pancreatic/duodenal homeobox-1 42 in streptozotocin-induced insulin-deficient rats. Therefore, the significantly reduced Leu concentration seen in our GK rats might partially reduce insulin-independent glucose uptake in skeletal muscle, and reduce whole body glucose oxidation and insulin secretion, leading to the increase of plasma glucose shown in Figure 3A .
It has been reported that Ile administration can stimulate muscle glucose uptake and whole body glucose oxidation, and depress gluconeogenesis in the liver, leading to the hypoglycemia. 36, 43 Ile stimulates insulin-independent glucose uptake in skeletal muscle, which might contribute to the plasma glucose-lowering effect seen in SD rats. 44 In our study, GK rat Ile concentrations were significantly reduced between 4 and 12 weeks, suggesting that the stimulating effect of Ile on insulin-independent glucose uptake in skeletal muscle might partially be weakened. Thus, a significantly reduced plasma Ile concentration could contribute to the elevated plasma glucose concentration in the GK rats.
The expression of GK rat Bckdha was higher than control suggesting that the mechanism of BCAA in T2D is complex and the further study is needed to investigate the exact mechanism of BCAA actions in T2D.
| CONCLUSION
In summary, the changes in the trends and levels of BCAA concen- humans and different T2D rat models, suggesting that the role of BCAA in T2D is complex. Elucidation of the mechanism by which BCAA contribute to T2D development in of GK rats needs further study.
